D. Catarzi

发表

Synthesis of some 2-aryl-1,2,4-triazolo[1,5-c][1,3]benzoxazin-5-ones as tools to define the essential pharmacophoric descriptors of a benzodiazepine receptor ligand.

C. Martini, A. Lucacchini, D. Catarzi, 1995, Journal of medicinal chemistry.

4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives

K. Varani, F. Vincenzi, D. Dal Ben, 2022, Pharmaceuticals.

The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype.

A. Cavalli, G. Marucci, M. Buccioni, 2017, Journal of medicinal chemistry.

Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A2A receptor as potential antitumor agents.

K. Varani, J. Sévigny, J. Pelletier, 2020, Bioorganic & medicinal chemistry letters.

Structural investigations on coumarins leading to chromeno[4,3-c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII.

C. Supuran, C. Ghelardini, A. Angeli, 2018, European journal of medicinal chemistry.

3-Hydroxy-1H-quinazoline-2,4-dione as a New Scaffold To Develop Potent and Selective Inhibitors of the Tumor-Associated Carbonic Anhydrases IX and XII.

C. Supuran, C. Ghelardini, A. Angeli, 2017, Journal of medicinal chemistry.

4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

S. Moro, Erika Morizzo, C. Martini, 2006, Journal of medicinal chemistry.

Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455

K. Varani, F. Vincenzi, S. Merighi, 2017, Front. Pharmacol..

Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A2A Adenosine Receptor Inverse Agonists with Antinociceptive Activity.

K. Varani, F. Vincenzi, P. Borea, 2016, Journal of medicinal chemistry.

1,2,4‐Benzothiadiazine‐1,1‐dioxide Derivatives as Ionotropic Glutamate Receptor Ligands: Synthesis and Structure–Activity Relationships

R. Matucci, D. Catarzi, V. Colotta, 2014, Archiv der Pharmazie.

Synthesis and biological evaluation of a new set of pyrazolo[1,5-c]quinazolines as glycine/N-methyl-D-aspartic acid receptor antagonists.

C. Costagli, A. Galli, D. Catarzi, 2009, Chemical & pharmaceutical bulletin.

Novel AMPA and kainate receptor antagonists containing the pyrazolo[1,5-c]quinazoline ring system: Synthesis and structure-activity relationships.

C. Costagli, A. Galli, Ombretta Lenzi, 2008, Bioorganic & medicinal chemistry.

Synthesis and pharmacological studies at the Gly/NMDA, AMPA and Kainate receptors of new oxazolo[4,5-c]quinolin-4-one derivatives bearing different substituents at position-2 and on the fused benzo ring.

C. Costagli, A. Galli, F. R. Calabri, 2005, European journal of medicinal chemistry.

Synthesis of 4-amino-6-(hetero)arylalkylamino-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent A(2A) adenosine receptor antagonists.

C. Martini, A. Lucacchini, L. Trincavelli, 2003, Bioorganic & medicinal chemistry.

Synthesis of a set of ethyl 1-carbamoyl-3-oxoquinoxaline-2-carboxylates and of their constrained analogue imidazo.

C. Costagli, A. Galli, D. Catarzi, 2001, European journal of medicinal chemistry.

Synthesis and A1 and A2A adenosine binding activity of some pyrano[2,3-c]pyrazol-4-ones.

C. Martini, A. Lucacchini, F. Melani, 1998, Farmaco.

Tricyclic Heteroaromatic Systems. Pyrazolo[3,4‐c]quinolin‐4‐ones and Pyrazolo[3,4‐c]quinoline‐1,4‐diones: Synthesis and Benzodiazepine Receptor Activity

C. Costagli, A. Galli, D. Catarzi, 1997, Archiv der Pharmazie.

Synthesis of some tricyclic heteroaromatic systems and their A1 and A2a adenosine binding activity

C. Martini, A. Lucacchini, D. Catarzi, 1995 .

Piperazine- and Piperidine-Containing Thiazolo[5,4-d]pyrimidine Derivatives as New Potent and Selective Adenosine A2A Receptor Inverse Agonists

K. Varani, F. Vincenzi, Silvia Pasquini, 2020, Pharmaceuticals.

Synthesis of 2-substituted-6,8-dichloro-3,4-dihydro-3-oxo-2H-1,4-benzothiazine-1,1-d ioxides and -1-oxides as glycine-NMDA receptor antagonists.

C. Costagli, A. Galli, D. Catarzi, 1998, Farmaco.

Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

S. Moro, Erika Morizzo, F. Pedata, 2009, Journal of medicinal chemistry.

1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.

S. Moro, F. Deflorian, C. Martini, 2004, Journal of medicinal chemistry.

Special Issue “Adenosine Receptors as Attractive Targets in Human Diseases”

D. Catarzi, V. Colotta, F. Varano, 2021, Pharmaceuticals.

Identification of novel thiazolo[5,4-d]pyrimidine derivatives as human A1 and A2A adenosine receptor antagonists/inverse agonists.

K. Varani, F. Vincenzi, Silvia Pasquini, 2018, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of analogues of 7-chloro-4,5-dihydro-4- oxo-8-(1,2,4-triazol-4-yl)-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylic acid (TQX-173) as novel selective AMPA receptor antagonists.

V. Carlá, C. Costagli, A. Galli, 2004, Journal of medicinal chemistry.

Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors. Ranging from Pan Ligands to Combined A1/A2B Partial Agonists

K. Varani, F. Vincenzi, D. Dal Ben, 2019, Pharmaceuticals.

Synthesis and biological evaluation of a new set of pyrazolo[1,5-c]quinazoline-2-carboxylates as novel excitatory amino acid antagonists.

V. Carlá, C. Costagli, A. Galli, 2002, Journal of medicinal chemistry.

Synthesis and structure-activity relationships of 1-aminophthalazinium salts as GABAA receptor antagonists

A. Galli, F. Mori, D. Catarzi, 1994 .

The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists.

S. Moro, C. Martini, S. Paoletta, 2011, Journal of medicinal chemistry.

1,2,4-Triazolo[1,5-a]quinoxaline derivatives: synthesis and biological evaluation as adenosine receptor antagonists.

C. Martini, A. Lucacchini, L. Trincavelli, 2004, Farmaco.

1,2,4-triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A₃ receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies.

C. Martini, M. Betti, D. Dal Ben, 2015, Bioorganic & medicinal chemistry.

1,2,4-Triazolo[1,5-a]quinoxaline as a Versatile Tool for the Design of Selective Human A3 Adenosine Receptor Antagonists: Synthesis, Biological Evaluation, and Molecular Modeling Studies of 2-(Hetero)aryl- and 2-Carboxy-Substitued Derivatives

S. Moro, C. Martini, L. Trincavelli, 2005 .

Structure-activity relationships of 1,2,4-triazolo[1,5-a] quinoxalines and their 1-deaza analogues imidazo[1,2-a]quinoxalines at the benzodiazepine receptor.

C. Martini, A. Lucacchini, L. Giusti, 1994, Journal of Medicinal Chemistry.

1-Substituted pyrazolo[1,5-c]quinazolines as novel Gly/NMDA receptor antagonists: synthesis, biological evaluation, and molecular modeling study.

S. Moro, F. Deflorian, C. Costagli, 2005, Bioorganic & medicinal chemistry.

Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand.

C. Costagli, A. Galli, D. Catarzi, 1996, Journal of medicinal chemistry.

Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Synthesis, pharmacological, and molecular modeling studies.

S. Moro, F. Deflorian, C. Ghelardini, 2006, Journal of medicinal chemistry.

Tricyclic heteroaromatic systems. Synthesis and A1 and A2a adenosine binding activities of some 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c] pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-b]quinolin-4- ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines.

C. Martini, A. Lucacchini, D. Catarzi, 1995, Journal of medicinal chemistry.

3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists.

C. Costagli, A. Galli, F. R. Calabri, 2004, Bioorganic & medicinal chemistry letters.

Synthesis, structure-affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.

K. Varani, G. Cristalli, F. Vincenzi, 2011, Bioorganic & medicinal chemistry.

New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

S. Moro, Erika Morizzo, F. Pedata, 2007, Journal of medicinal chemistry.

Pharmacological characterization of some selected 4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates and 3-hydroxyquinazoline-2,4-diones as (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor antagonists.

K. Lingenhöhl, S. Ofner, Ombretta Lenzi, 2010, Chemical & pharmaceutical bulletin.

The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor.

K. Varani, F. Vincenzi, M. Betti, 2018, European journal of medicinal chemistry.

Synthesis and biological evaluation of novel 9-heteroaryl substituted 7-chloro-4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates (TQX) as (R,S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) receptor antagonists.

Jacopo Sgrignani, P. Gratteri, C. Costagli, 2008, Chemical & pharmaceutical bulletin.

Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.

S. Moro, Erika Morizzo, F. Pedata, 2008, Bioorganic & medicinal chemistry.

1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.

S. Moro, C. Martini, L. Trincavelli, 2005, Journal of medicinal chemistry.

Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular docking analysis and pharmacological studies.

K. Varani, G. Cristalli, F. Vincenzi, 2009, Bioorganic & medicinal chemistry.

Development of novel pyridazinone-based adenosine receptor ligands.

K. Varani, F. Vincenzi, D. Dal Ben, 2018, Bioorganic & medicinal chemistry letters.

Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes.

F. Pedata, I. Palchetti, K. Varani, 2017, European journal of medicinal chemistry.

The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles

M. Sturlese, S. Moro, K. Varani, 2017, Journal of enzyme inhibition and medicinal chemistry.

Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors.

K. Varani, F. Vincenzi, M. Betti, 2016, Bioorganic & medicinal chemistry.

Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation.

K. Varani, F. Vincenzi, M. Betti, 2015, European journal of medicinal chemistry.

7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigations at the 5-position to target human A₁ and A(2A) adenosine receptors. Molecular modeling and pharmacological studies.

S. Moro, K. Varani, F. Vincenzi, 2014, European journal of medicinal chemistry.

2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation.

S. Moro, K. Varani, C. Corciulo, 2013, Journal of medicinal chemistry.

Tricyclic Heteroaromatic Systems. 1,2,4‐Triazolo[4,3‐a]quinoxalines and 1,2,4‐Triazino[4,3‐a]quinoxalines: Synthesis and Central Benzodiazepine Receptor Activity

C. Costagli, A. Galli, D. Catarzi, 1997, Archiv der Pharmazie.

Competitive AMPA receptor antagonists

D. Catarzi, V. Colotta, F. Varano, 2007, Medicinal research reviews.

Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells.

G. Marucci, M. Buccioni, C. Ghelardini, 2019, Bioorganic chemistry.

Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor.

S. Moro, K. Varani, F. Vincenzi, 2016, European journal of medicinal chemistry.

Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain.

G. Marucci, M. Buccioni, C. Ghelardini, 2019, Journal of medicinal chemistry.

Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents.

C. Supuran, G. Marucci, M. Buccioni, 2020, European journal of medicinal chemistry.

Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives with High Affinity for Both the Adenosine A1 and A2A Receptors, and Efficacy in Animal Models of Depression

G. Marucci, M. Buccioni, C. Ghelardini, 2021, Pharmaceuticals.

New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists.

G. Marucci, M. Buccioni, D. Dal Ben, 2020, Bioorganic & medicinal chemistry letters.

Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity.

G. Marucci, M. Buccioni, D. Dal Ben, 2019, Bioorganic & medicinal chemistry letters.

“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies

S. Moro, S. Federico, G. Spalluto, 2023, Pharmaceuticals.

Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity.

K. Varani, C. Ghelardini, G. Bartolucci, 2019, Journal of medicinal chemistry.

Structure-activity relationship studies and pharmacological characterization of N5-heteroarylalkyl-substituted-2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based derivatives as inverse agonists at human A2A adenosine receptor.

K. Varani, F. Vincenzi, P. Borea, 2018, European journal of medicinal chemistry.

Adenosine A2B receptors inhibit K+ currents and cell differentiation in cultured oligodendrocyte precursor cells and modulate sphingosine-1-phosphate signaling pathway.

F. Pedata, P. Bruni, E. Coppi, 2020, Biochemical pharmacology.

Synthesis and structure-activity relationships of a new set of 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as adenosine receptor antagonists.

C. Martini, A. Lucacchini, L. Trincavelli, 2003, Bioorganic & medicinal chemistry.

Benzodiazepine binding activity of some tricyclic heteroaromatic systems to define the hydrogen bonding strength of the proton donors of the receptor site

C. Costagli, A. Galli, F. Melani, 1996 .

Structure‐Activity Relationship Studies of Novel Pyrazolo[1,5‐c][1,3]benzoxazines: Synthesis and Benzodiazepine Receptor Affinity

C. Costagli, A. Galli, D. Catarzi, 1996, Archiv der Pharmazie.

7-Chloro-4,5-dihydro-8-(1,2,4-triazol-4-yl)-4-oxo-1,2,4-triazolo[1, 5-a]quinoxaline-2- carboxylates as novel highly selective AMPA receptor antagonists.

V. Carlá, C. Costagli, A. Galli, 2000, Journal of medicinal chemistry.

Functional characterization of a novel adenosine A2B receptor agonist on short-term plasticity and synaptic inhibition during oxygen and glucose deprivation in the rat CA1 hippocampus

F. Pedata, E. Coppi, Irene Fusco, 2019, Brain Research Bulletin.

1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists.

C. Martini, A. Lucacchini, V Colotta, 2000, Journal of medicinal chemistry.

Pharmacological Characterization of P626, a Novel Dual Adenosine A2A/A2B Receptor Antagonist, on Synaptic Plasticity and during an Ischemic-like Insult in CA1 Rat Hippocampus

F. Pedata, E. Coppi, A. Pugliese, 2023, Biomolecules.

Synthesis and Biological Evaluation of a Series of Quinazoline‐2‐carboxylic Acids and Quinazoline‐2,4‐diones as Glycine‐NMDA Antagonists: A Pharmacophore Model Based Approach

C. Costagli, A. Galli, D. Catarzi, 1997, Archiv der Pharmazie.

CK1 delta inhibition: an emerging strategy to combat neurodegenerative diseases.

D. Catarzi, V. Colotta, F. Varano, 2022, Future medicinal chemistry.

3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies.

S. Moro, F. Pedata, Davide Sabbadin, 2012, European journal of medicinal chemistry.

2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.

S. Moro, Erika Morizzo, K. Varani, 2009, Journal of medicinal chemistry.

Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study.

S. Moro, Erika Morizzo, K. Varani, 2007, Journal of medicinal chemistry.

2-aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists.

S. Moro, C. Martini, F. R. Calabri, 2005, Bioorganic & medicinal chemistry.

Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.

C. Martini, A. Lucacchini, L. Trincavelli, 2000, Journal of medicinal chemistry.

Abstracts from the 2017 Italian-German Purine Club Meeting

T. Schöneberg, L. Marnett, E. Kostenis, 2017, Purinergic Signalling.

Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structure-affinity relationships and molecular modeling studies.

K. Varani, G. Cristalli, F. Vincenzi, 2013, Bioorganic & medicinal chemistry.

Tandem 3D-QSARs approach as a valuable tool to predict binding affinity data: design of new Gly/NMDA receptor antagonists as a key study.

Stefano Moro, Magdalena Bacilieri, Flavia Varano, 2007, Journal of chemical information and modeling.

Competitive Gly/NMDA receptor antagonists.

D. Catarzi, V. Colotta, F. Varano, 2006, Current topics in medicinal chemistry.

Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates analogues of TQX-173.

C. Costagli, A. Galli, D. Catarzi, 2001, Journal of medicinal chemistry.

4,5-Dihydro-1,2,4-triazolo[1,5-a]quinoxalin-4-ones: excitatory amino acid antagonists with combined glycine/NMDA and AMPA receptor affinity.

C. Costagli, D. Catarzi, L. Cecchi, 1999, Journal of medicinal chemistry.

4‐Amino‐6‐benzylamino‐1,2‐dihydro‐2‐phenyl‐1,2,4‐triazolo[4,3‐α]‐quinoxalin‐1‐one: A New A2A Adenosine Receptor Antagonist with High Selectivity versus A1 Receptors

C. Martini, L. Trincavelli, D. Catarzi, 1999, Archiv der Pharmazie.

4‐Amino‐6‐benzylamino‐1,2‐dihydro‐2‐phenyl‐1,2,4‐triazolo [4,3‐a]quinoxalin‐1‐one: A New A2A Adenosine Receptor Antagonist with High Selectivity versus A1 Receptors.

C. Martini, A. Lucacchini, L. Trincavelli, 1999 .